Title: 
Official Title: 
Number of Sections: 1
Source: versions - Introduced
Media Type: text/html

================================================================================

Section 1:
Senate File 433 - Introduced SENATE FILE 433 BY WAHLS A BILL FOR An Act relating to direct acting antiviral medications, 1 including prior authorization requirements, and the Iowa 2 medical assistance drug utilization review commission. 3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 4 TLSB 1440XS (4) 91 lh/ko S.F. 433 Section 1. DIRECT ACTING ANTIVIRAL MEDICATION ââ MEDICAID 1 PRIOR AUTHORIZATION. Notwithstanding section 249A.20A, 2 subsection 4, the department of health and human services shall 3 not require prior authorization for any direct acting antiviral 4 medications used to treat hepatitis C that are on the preferred 5 drug list. 6 Sec. 2. IOWA MEDICAL ASSISTANCE DRUG UTILIZATION REVIEW 7 COMMISSION ââ VOSEVI REVIEW. The Iowa medical assistance drug 8 utilization review commission created under section 249A.24 9 shall, by July 1, 2026, review the prescription drug vosevi for 10 placement on the preferred drug formulary pursuant to 42 U.S.C. 11 Â§1396r-8 as a preferred direct acting antiviral for treatment 12 of hepatitis C. 13 EXPLANATION 14 The inclusion of this explanation does not constitute agreement with 15 the explanationâs substance by the members of the general assembly. 16 This bill relates to direct acting antivirals, including 17 prior authorization requirements, and the Iowa medical 18 assistance drug utilization review commission (commission). 19 The bill prohibits the department of health and human 20 services from requiring prior authorization for direct acting 21 antiviral medications used to treat hepatitis C that are on the 22 preferred drug list for the medical assistance program. 23 The bill requires the commission to review, by July 1, 2026, 24 the prescription drug vosevi for placement on the preferred 25 drug list pursuant to 42 U.S.C. Â§1396r-8 as a preferred direct 26 acting antiviral for treatment of hepatitis C. 27 -1- LSB 1440XS (4) 91 lh/ko 1/ 1


================================================================================

Raw Text:
Senate File 433 - Introduced SENATE FILE 433 BY WAHLS A BILL FOR An Act relating to direct acting antiviral medications, 1 including prior authorization requirements, and the Iowa 2 medical assistance drug utilization review commission. 3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 4 TLSB 1440XS (4) 91 lh/ko S.F. 433 Section 1. DIRECT ACTING ANTIVIRAL MEDICATION ââ MEDICAID 1 PRIOR AUTHORIZATION. Notwithstanding section 249A.20A, 2 subsection 4, the department of health and human services shall 3 not require prior authorization for any direct acting antiviral 4 medications used to treat hepatitis C that are on the preferred 5 drug list. 6 Sec. 2. IOWA MEDICAL ASSISTANCE DRUG UTILIZATION REVIEW 7 COMMISSION ââ VOSEVI REVIEW. The Iowa medical assistance drug 8 utilization review commission created under section 249A.24 9 shall, by July 1, 2026, review the prescription drug vosevi for 10 placement on the preferred drug formulary pursuant to 42 U.S.C. 11 Â§1396r-8 as a preferred direct acting antiviral for treatment 12 of hepatitis C. 13 EXPLANATION 14 The inclusion of this explanation does not constitute agreement with 15 the explanationâs substance by the members of the general assembly. 16 This bill relates to direct acting antivirals, including 17 prior authorization requirements, and the Iowa medical 18 assistance drug utilization review commission (commission). 19 The bill prohibits the department of health and human 20 services from requiring prior authorization for direct acting 21 antiviral medications used to treat hepatitis C that are on the 22 preferred drug list for the medical assistance program. 23 The bill requires the commission to review, by July 1, 2026, 24 the prescription drug vosevi for placement on the preferred 25 drug list pursuant to 42 U.S.C. Â§1396r-8 as a preferred direct 26 acting antiviral for treatment of hepatitis C. 27 -1- LSB 1440XS (4) 91 lh/ko 1/ 1